|
|
NielsBohrweg 11
Leiden, 2333 CA Netherlands
phone:(31) (0) 71 3322255
fax:(31) (0) 84 8709728
|
|
| Symbol |
Private |
| Founded |
2004 |
| Employees |
15 |
|
|
| www.toBBB.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| CNS Drug Delivery |
|
| Management |
| Willem W. van Weperen (1967) MBA, MSc, Chief Executive Officer; Pieter J. Gaillard (1968), PhD, Chief Scientific Officer |
| |
|
|
| |
|
| Keywords |
| drugs, delivery, targeted, blood, bbb, cns |
|
|
|
| Description |
|
to-BBB 's proprietary G-Technology for CNS drug targeting is being used for internal drug development (lead product 2B3-101 in brain cancer) and licensing to pharma for brain delivery of their compounds. |
|
| Products / Services |
to-BBB's lead product for brain cancer 2B3-101 has shown therapeutic benefit and a predictable safety profile in pre-clinical studies and the product is ready to enter clinical trials in 2011.
|
|
| Technology / Differentiation |
| to-BBB's proprietary G-Technology is a safe technology for drug delivery to the brain. It is based on liposomes that are coated with the tripeptide glutathione at the tips of polyethylene glycol (PEG) to safely enhance the delivery of free drug to the brain. Proof of concept with the
G-Technology is demonstrated in several disease models, including pain, brain tumors and viral encephalitis. |
|
| Market / Customers |
Since Q3 2009 to-BBB has established research collaborations with several pharma companies around brain delivery of their compounds. These companies include MedImmune, Shire, Genzyme, Lundbeck, GSK, Janssen, Abbott and two undisclosed top-10 pharma companies.
|
|
| Competitors / Substitutes / Alternatives |
There is limited competition and a large open area in the field of brain drug delivery. The safety and flexibility of to-BBB's enhanced brain drug delivery platform has lead to a very high interest by pharma as illustrated by the 10 collaborations.
|
|
| Strategy |
to-BBB 's proprietary G-Technology for CNS drug targeting is being used for internal drug development and licensing to pharma.
|
|
| Funding |
| In 2007 the company raised 4M in a series-A round with Aescap Venture in the Netherlands. |
|
| Status |
| to-BBB is preparing a series-B round of 8M to generate value with a phase I/II study in brain cancer and the first license deals with pharma. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members